Early recognition of an “IL-1β–oxidative” profile or a “TNF-lipid” profile could enable targeted preventive strategies, hypothetically including antioxidant-rich diet and inflammasome inhibition for the former [37,44]; and early dyslipidemia control and, where appropriate, TNF blockade for the latter [39,45], pending further validation. This evidence concerns the gene TNF and metabolic syndrome.